<p>depends on the product</p>
<p>For instance, an IBD analyst whose goal is to get into PE probably cant go wrong with MS, but unless I have other choices, I definitely would not go to MS because I am interested in S&T, and MS has been stinking it up on the trading floor, especially in the fixed income space.</p>
<p>Someone’s who’s interested in fixed income product/structured products across all asset classes would never go wrong with Barcap, but the IBD franchise especially outside the US is lackluster, and the cash equity business is junk too (they actually just started the cash equity platform in HK/Japan)</p>
<p>I can go on and on…</p>